Only briefly SBIR involved and at that time described as developing antigen-specific immunotherapeutics, Selecta Biosciences Inc (NASDAQ:SELB) is a clinical-stage biopharmaceutical company structured around research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The firm's proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. Lead product - SEL-212 -- has completed Phase II clinical trials for the treatment of chronic refractory gout. The firm is also involved in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has various license and collaboration agreements with Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; BIND Therapeutics, Inc.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc.
